Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors from the central nervous technique, conolidine modulates alternate molecular targets. A Science Developments research observed that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7,